Mukundan Attur, Ph.D. – associate professor, department of medicine, NYU Grossman School of MedicinePhilip Conaghan, M.D. – professor of musculoskeletal medicine, University of Leeds, U.K.Marc C. Hochberg, M.D., MPH, MACP, MACR – professor of medicine and epidemiology & public health, head, division of rheumatology and clinical immunology, and vice chair, department of medicine, University of Maryland School of Medicine, and director, Medical Care Clinical Center, Veteran Affairs Maryland Health Care SystemVirginia Byers Kraus, M.D, Ph.D. – professor of medicine, pathology, and orthopaedic surgery, and faculty member, Duke Molecular Physiology Institute, Duke University School of MedicineNancy E. Lane, M.D. – endowed professor of medicine, rheumatology, and aging research, director of the Center for Musculoskeletal Health, and director of the K12 National Institutes of Health (NIH) Building Interdisciplinary Research Careers in Women's Health at the University of California at Davis School of MedicineThomas J. Schnitzer, M.D., Ph.D. – professor of physical medicine and rehabilitation, anesthesiology, and medicine (rheumatology), Northwestern University Feinberg School of MedicineJohn Fraser Wright, Ph.D. – professor of pediatrics in the Center for Definitive and Curative Medicine, Stanford University; scientific co-founder of Kriya Therapeutics; co-founder and former chief technology officer, Spark TherapeuticsGenascence was founded in 2017, in Palo Alto, California, by a team of experts and industry leaders with deep experience and proven track record in the design, development, and manufacturing of successful gene therapies and biological medicines, and company building.Thomas Chalberg, Ph.D. – founder and CEO; managing director, Polymerase Capital; founder and CEO, SightGlass Vision; chief operating officer, Oncorus, Inc.; founder and CEO, Avalanche BiotechnologiesChristopher H. Evans, Ph.D. – founder; John and Posy Krehbiel Professor of Orthopedics and director of the Musculoskeletal Gene Therapy Research Laboratory, Mayo ClinicSteven Ghivizzani, Ph.D. – founder; professor and director of orthopedic gene therapy, University of Florida College of MedicineAnnahita Keravala, Ph.D. – founder; senior vice president and head of gene therapy, CODA Biotherapeutics; associate vice president and head of AAV platform, Rocket Pharmaceuticals; director of research, Adverum BiotechnologiesPaul Robbins, Ph.D. – founder; professor of biochemistry, molecular biology, and biophysics, University of MinnesotaThe company completed a seed round of financing in 2019 led by Polymerase Capital. In addition, the company announced that additional data from the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA), including 12-month follow up on all subjects, will be presented in a poster session at the upcoming American Society of Gene & Cell Therapy's (ASGCT) 25th Annual Meeting being held virtually and in-person May 16-19, 2022, in Washington, D.C. Genascence, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, is developing life-changing treatments for highly prevalent conditions affecting millions of people.